HIGHFDA DEVICE

Inpeco Recall: 8 FlexLab FLX Potassium Test System Units Over Unverified HIL Function (2025)

Inpeco recalled eight FlexLab FLX System Potassium Test System units sold in California and New York. The recall targets the Sample Integrity Module HIL function, which detects hemolysis, icterus and lipemia. The FDA has not evaluated this function for safety or effectiveness, risking erroneous results or delays. Labs should stop using the device immediately.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DEVICE
Recall date
September 3, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
September 3, 2025
Hazard Level
HIGH
Brand
Inpeco
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
2 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Medical Devices; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Inpeco
Product type
Potassium Test System
Model numbers
FLX-056-01, FLX-056-11, FLX-0204, FLX-0205, FLX-0209, FLX-0210, FLX-0216, FLX-0220 +2 more
Sold at
Unknown
Where affected
CA, NY

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    September 3, 2025

  2. Reported by FDA DEVICE

    October 15, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

The FlexLab System Sample Integrity Module (SIM) includes function that determines the hemolysis, icterus, and lipemia (HIL) in blood samples. This function has not been evaluated for safety and effectiveness by the FDA, so its use may cause an increase in erroneous results or a delay in patient results.

What You Should Do

Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Inpeco S.A. or your healthcare provider for instructions. Notification method: E-Mail

About This Product

The FlexLab System is a laboratory instrument used for clinical chemistry testing. The Potassium Test System is part of this platform. The Sample Integrity Module verifies sample quality indicators such as HIL. This recall concerns the HIL function within SIM.

Why This Is Dangerous

The SIM HIL function has not been evaluated by the FDA for safety and effectiveness. Using it may lead to incorrect results or delays in reporting patient results.

Industry Context

This recall is not described as part of a broader industry pattern in the provided information.

Real-World Impact

Healthcare labs may experience data integrity issues or result delays if HIL data is unreliable, potentially affecting patient care and workflow.

Practical Guidance

How to identify if yours is affected

  1. Check model numbers and serials: FLX-056-01, FLX-056-11, FLX-0204, FLX-0205, FLX-0209, FLX-0210, FLX-0216, FLX-0220, FLX-0221, FLX-0222.
  2. Look for UDI 07640172340004 with Serial FLX.0204.
  3. Review facility inventory for FlexLab FLX System units.

Where to find product info

Identifiers are on device labels, packaging, and the associated documentation provided with the unit.

What timeline to expect

There is no public timeline provided in the recall for refunds or replacements. Expect manufacturer guidance via recall notice updates.

If the manufacturer is unresponsive

  • Document attempts to contact Inpeco S.A. and facility leadership.
  • If the manufacturer is unresponsive, contact the FDA for guidance on next steps.

How to prevent similar issues

  • Verify FDA clearance and safety validation for all HIL-related features before deployment.
  • Maintain an up-to-date inventory of critical diagnostic modules and their recall status.
  • Establish a protocol to quarantine devices under recall and document communications.

Documentation advice

Keep a copy of the recall notice, inventory lists, serial numbers, dates of purchase, internal communications, and any correspondence with the manufacturer.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Model numbers: FLX-056-01, FLX-056-11, FLX-0204, FLX-0205, FLX-0209, FLX-0210, FLX-0216, FLX-0220, FLX-0221, FLX-0222. Sold in the United States with distribution to California and New York. Quantity: 8 units. Brand: Inpeco. Status: Active recall. SoldFrom: Unknown. SoldTo: CA, NY. Price: Unknown.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • US distribution to CA & NY
  • HIL function not FDA evaluated
  • Possible erroneous results or delayed results
  • Stop using immediately
  • Model numbers include FLX-056-01, FLX-056-11, FLX-0204, FLX-0205, FLX-0209, FLX-0210, FLX-0216, FLX-

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Details

Brand
Model Numbers
FLX-056-01
FLX-056-11
FLX-0204
FLX-0205
FLX-0209
+5 more
Affected States
CA, NY
Report Date
October 15, 2025
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more